Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Japan Q1 Roundup: Enhertu, Padcev, Actemra and Lenvima Push Growth

Aug 09 2022

• By Lisa Takagi

Japan q1 round up — Daiichi Sankyo, Chugai, Astellas, Eisai show stable Q1 growth • Source: Shutterstock

Related Content

Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data

Jun 17 2022

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

Jun 06 2022

Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study

Sep 15 2021

Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval

Aug 05 2022

Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Jul 26 2022

Related Companies

Daiichi Sankyo Co., Ltd.

Astellas Pharma, Inc.

Chugai Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

Roche Holding AG

Astellas Gene Therapies

Maruho Co., Ltd.

Bristol Myers Squibb Company

Biogen, Inc.

Additional Topics

Japan Asia Pacific Business Strategies Research & Development BioPharmaceutical

More from Japan

More from Focus On Asia

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window